Fluorescence Surgery for Sentinel Node Identification in Melanoma

Sponsor
Barretos Cancer Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT02142244
Collaborator
(none)
318
1
1
91
3.5

Study Details

Study Description

Brief Summary

Sentinel node biopsy is a surgical procedure used to find melanoma lymph node metastasis (i.e. groin/axilla) in very early stages. This study aims to add a new technology over the standard procedure - a fluorescent contrast (indocyanine green) using special light (near infra-red) - looking for more precise diagnosis of the presence of the lymph node metastasis.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Near infra red sentinel node biopsy
  • Drug: Indocyanine green
  • Device: Intraoperative Near-Infrared Imaging System
N/A

Detailed Description

The main objectives of this study is perform a new technique added to the usual procedure for sentinel lymph node biopsy for cutaneous melanoma. The fluorescence surgery consists in a injection of indocyanine green around the primary tumor, or, when already excised (excisional biopsy), the biopsy site at the beginning of the surgery. Patient performs, in a standard fashion, the lymph scintigraphy prior the surgery and is injected at the same time a blue die similarly the indocyanine green. Immediately after the indocyanine infusion, the injection site is massaged and a near infra red light (NIR) is focused over it. An appropriated infra red camera is positioned over the lymphatic pathway, searching for the fluorescence and localizing the sentinel node at the basin. The skin is opened and the sentinel node is resected. The success or not in localizing the sentinel node is pointed and the standard techniques are applied - gamma probe and surgical location of a blue lymph node. All sentinel node characteristics are noted as number, which technic identified it, time, location. Later information will be gathered as histological status, surgical complications, recurrence and survival.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
318 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Infrared Fluorescence Guided Surgery for Sentinel Node Identification in Cutaneous Melanoma
Study Start Date :
May 1, 2014
Anticipated Primary Completion Date :
Dec 1, 2018
Anticipated Study Completion Date :
Dec 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Near infra red sentinel node biopsy

Sentinel node biopsy adding indocyanine green injection at the tumor/biopsy site during the surgical procedure to the standard technique (blue die and lymph scintigraphy) and near infra red light for fluorescence. The indocyanine green saline solution - 5mg diluted in 10ml. will be injected in 4 points around the biopsy site - 4ml each - total 0.8mg - single procedure.Near infra red lens and camera will be used to detect the fluorescence and localize the sentinel node for biopsy.

Procedure: Near infra red sentinel node biopsy
Explicated in the protocol arm
Other Names:
  • Sentinel node biopsy with fluorescence
  • Drug: Indocyanine green
    Explicated in the protocol arm

    Device: Intraoperative Near-Infrared Imaging System
    Explicated in the protocol arm
    Other Names:
  • Photodynamic Eye (PDE)
  • Pulsion
  • MiniFlare
  • The Flare Foundation
  • Outcome Measures

    Primary Outcome Measures

    1. Sensibility of the sentinel node biopsy [Time of surgery]

      The successful rate of the sentinel node localization and biopsy. The standard technique and the experimental one will be assessed

    Secondary Outcome Measures

    1. Specificity of the sentinel node biopsy [60 months]

      The false negative sentinel node biopsy rate. The proportion of patients submitted to the procedure with histological negative biopsy, presenting lymph node metastasis at follow up.

    Other Outcome Measures

    1. Overall survival [60 months]

    2. Disease free survival [60 months]

      Presence and time to disease recurrence or not

    3. Specific cancer survival [60 months]

      Specific melanoma survival

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients eligible for sentinel node biopsy in standard care
    Exclusion Criteria:
    • Previous neoplasia

    • Previous surgery or scar in the lymph node basin or primary tumor, except primary tumor biopsy

    • Local recurrence

    • Hypersensibility or allergy history to indocyanine or Iodine-based contrast media

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Barretos Cancer Hospital Barretos SP Brazil 14784400

    Sponsors and Collaborators

    • Barretos Cancer Hospital

    Investigators

    • Principal Investigator: Vinicius L Vazquez, Ph.D., Barretos Cancer Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Barretos Cancer Hospital
    ClinicalTrials.gov Identifier:
    NCT02142244
    Other Study ID Numbers:
    • BCHNIR01
    First Posted:
    May 20, 2014
    Last Update Posted:
    Feb 2, 2017
    Last Verified:
    Sep 1, 2016
    Keywords provided by Barretos Cancer Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 2, 2017